The metabolism and excretion of trimethadione in patients with percutaneous transhepatic biliary drainage and renal dysfunction.
The metabolism and excretion of trimethadione (TMO) following an oral dose of 4 mg/kg has been examined in patients with percutaneous transhepatic biliary drainage (PTBD) and renal dysfunction. Biliary excretion as the total amount of TMO and its metabolite, dimethadione (DMO) was 2.0% of the dose during 0 to 48 h after TMO administration in patients with PTBD. Total urinary excretion (0-48 h) was 2.8% and 3.0% of the dose in healthy volunteers and patients with renal dysfunction, respectively. The serum DMO/TMO ratio at 4 h after oral dosing in patients of PTBD and renal dysfunction was not significantly changed in comparison with the ratio reported previously in healthy volunteers. The elimination half-life of TMO was also not altered in patients with PTBD in comparison with that reported previously in volunteers. These results suggest that metabolism and urinary and biliary excretion of TMO are not changed in patients with PTBD and renal dysfunction.
Tanaka
E
E
Institute of Community Medicine, University of Tsukuba, Ibaraki-ken, Japan.
Ishikawa
A
A
Yamamoto
Y
Y
Fukao
K
K
Iwasaki
Y
Y
Misawa
S
S
D000328:Adult; D000368:Aged; D001646:Bile / Q000378:metabolism*; D001660:Biliary Tract Diseases / Q000378:metabolism*; D004114:Dimethadione / Q000378:metabolism; D005260:Female; D006207:Half-Life; D006801:Humans; D007674:Kidney Diseases / Q000378:metabolism*; D008297:Male; D008875:Middle Aged; D010080:Oxazoles / Q000493:pharmacokinetics*; D014293:Trimethadione / Q000493:pharmacokinetics* / Q000652:urine
D010080:Oxazoles; D004114:Dimethadione; D014293:Trimethadione